Cooper Companies (NASDAQ:COO) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Cooper Companies (NASDAQ:COO) in a report issued on Thursday, Benzinga reports.

Other equities research analysts have also issued reports about the company. Robert W. Baird upped their price target on Cooper Companies from $118.00 to $125.00 and gave the company an outperform rating in a research report on Thursday. Wells Fargo & Company raised their target price on Cooper Companies from $110.00 to $115.00 and gave the stock an overweight rating in a research note on Thursday. Piper Sandler lifted their price target on Cooper Companies from $115.00 to $120.00 and gave the stock an overweight rating in a report on Thursday. Finally, Jefferies Financial Group raised shares of Cooper Companies from a hold rating to a buy rating and upped their price objective for the company from $107.00 to $115.00 in a report on Tuesday, July 16th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $113.61.

Cooper Companies Stock Performance

Shares of COO stock opened at $105.73 on Thursday. Cooper Companies has a fifty-two week low of $75.93 and a fifty-two week high of $106.95. The firm has a market capitalization of $21.05 billion, a P/E ratio of 62.19, a PEG ratio of 2.34 and a beta of 0.98. The stock’s fifty day moving average is $91.53 and its two-hundred day moving average is $94.21. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.14 and a current ratio of 1.95.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.11% and a return on equity of 8.87%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same period last year, the firm posted $0.84 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Research analysts expect that Cooper Companies will post 3.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors have recently made changes to their positions in COO. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Cooper Companies by 248.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after acquiring an additional 174 shares during the last quarter. Innealta Capital LLC purchased a new stake in Cooper Companies in the second quarter valued at approximately $25,000. Covestor Ltd lifted its stake in Cooper Companies by 305.9% during the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after purchasing an additional 208 shares in the last quarter. Crewe Advisors LLC boosted its position in shares of Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Cooper Companies by 358.6% during the first quarter. Global Retirement Partners LLC now owns 321 shares of the medical device company’s stock worth $33,000 after buying an additional 251 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.